Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 12/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507513 | 0.93 | HSD11B1 (0.47) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4501724 | 0.93 | HSD11B1 (0.46) | HSD11B1CYP2D6AVPR1ANPY5RHRH3 | |
| SCHEMBL4501727 | 0.93 | HSD11B1 (0.46) | HSD11B1CYP2D6AVPR1ANPY5RHRH3 | |
| SCHEMBL4521344 | 0.90 | PDK2 (0.48) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4519975 | 0.90 | PDK2 (0.48) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4526266 | 0.90 | PDK2 (0.48) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4526269 | 0.90 | PDK2 (0.48) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4525663 | 0.89 | HSD11B1 (0.43) | HSD11B1CYP2D6AVPR1ANPY5R | |
| SCHEMBL4517416 | 0.89 | PDK2 (0.51) | HSD11B1CYP2D6PDK2AVPR1ANPY5R | |
| SCHEMBL4517418 | 0.89 | PDK2 (0.51) | HSD11B1CYP2D6PDK2AVPR1ANPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | claimed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | claimed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | INCYTE CORPORATION, A DELAWARE CORPORATION | 2009-12-03 | — | — | US | disclosed |
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | INCYTE CORPORATION | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122210-A1 | Inhibitors of 11-beta hydroxyl steroid dehydrogenase type I and methods of using the same | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2D6 253/4885PDK2 609/4885 |
| US-20090298808-A1 | INHIBITORS OF 11-BETA HYDROXYL STEROID DEHYDROGENASE TYPE I AND METHODS OF USING THE SAME | HSD11B1, HSD11B2, HSD17B1 | HSD11B1 1/4885CYP2D6 253/4885PDK2 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.